Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

89.52 +2.57 (+2.96%)

Streaming Delayed Price Updated: 2:54 PM EDT, Jul 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	583,128
Open	87.07
Bid (Size)	89.48 (100)
Ask (Size)	89.56 (100)
Prev. Close	86.95
Today's Range	86.04 - 91.00
52wk Range	28.66 - 91.00
Shares Outstanding	115,926,629
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 High-Flying Stocks We Steer Clear Of

June 30, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Via StockStory

3 Unpopular Stocks We Steer Clear Of

June 23, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Performance

YTD	+134.3%	+134.3%
1 Month	+27.1%	+27.1%
3 Month	+122.1%	+122.1%
6 Month	+27.5%	+27.5%
1 Year	+22.0%	+22.0%

More News

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

June 17, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

June 06, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗

April 30, 2026

Via Chartmill

1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

June 01, 2026

Via StockStory

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

May 27, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

3 Reasons to Sell CORT and 1 Stock to Buy Instead

May 12, 2026

Via StockStory

3 High-Flying Stocks We Think Twice About

May 11, 2026

Via StockStory

Corcept (CORT) Q1 2026 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Corcept (CORT) Q4 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Corcept (CORT) Q1 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Corcept (CORT) Q2 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

May 04, 2026

Via StockStory

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

April 30, 2026

Via StockStory

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

April 30, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

April 30, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Earnings: What To Look For From CORT

April 28, 2026

Via StockStory

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

April 23, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

April 21, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT

April 21, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore

April 21, 2026

Via StockStory

CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st

April 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?

Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.

What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?

Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?

The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market

What is the current price of Corcept Therapeutics Incorporated - Common Stock?

The current price of Corcept Therapeutics Incorporated - Common Stock is 89.52

When was Corcept Therapeutics Incorporated - Common Stock last traded?

The last trade of Corcept Therapeutics Incorporated - Common Stock was at 07/01/26 02:54 PM ET

What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?

The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 10.38B

How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?

Corcept Therapeutics Incorporated - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.